Literature DB >> 15160242

[82-year old patient with hyperostosis frontalis, prognathism, makroglossia and cutis gyrata. Acromegaly].

H Mönnich1, B O Böhm, H Weidenbach.   

Abstract

We present a 82 year old female patient with typical acral enlargement. There were no signs of visceromegaly. Magnetic resonance imaging of the pituitary region showed a macroadenoma. Oral glucose tolerance test revealed missing suppression of the Human Growth Hormone (HGH), which could be achieved with a long acting somatostatin analog. A HGH suppressive therapy with a long acting dopamine agonist (Cabergolin) was induced. The patient died one year later following cardiovascular complications.

Entities:  

Mesh:

Year:  2004        PMID: 15160242     DOI: 10.1007/s00108-004-1194-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  13 in total

1.  Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion.

Authors:  H Rau; P H Althoff; K Schmidt; K H Usadel
Journal:  Acta Endocrinol (Copenh)       Date:  1992-03

2.  Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.

Authors:  N R Biermasz; H van Dulken; F Roelfsema
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

Review 3.  Medical therapy for acromegaly.

Authors:  C B Newman
Journal:  Endocrinol Metab Clin North Am       Date:  1999-03       Impact factor: 4.741

4.  Failure of radiotherapy in acromegaly.

Authors:  R Cozzi; M Barausse; D Asnaghi; D Dallabonzana; S Lodrini; R Attanasio
Journal:  Eur J Endocrinol       Date:  2001-12       Impact factor: 6.664

Review 5.  [Therapy of pituitary diseases. What can be achieved with medication and hormones?].

Authors:  J Schopohl; B Gutt
Journal:  MMW Fortschr Med       Date:  2001-11-01

6.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Authors:  A Colao; D Ferone; P Marzullo; P Cappabianca; S Cirillo; V Boerlin; I Lancranjan; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

7.  Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.

Authors:  V S Herman-Bonert; K Zib; J A Scarlett; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

8.  Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients.

Authors:  G Minniti; M L Jaffrain-Rea; R Baldelli; E Ferretti; B Caracciolo; A Bultrini; A Gulino; G Tamburrano
Journal:  Clin Ter       Date:  1997-12

Review 9.  Pituitary disorders. Drug treatment options.

Authors:  J J Orrego; A L Barkan
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

10.  Octreotide as primary therapy for acromegaly.

Authors:  C B Newman; S Melmed; A George; D Torigian; M Duhaney; P Snyder; W Young; A Klibanski; M E Molitch; R Gagel; L Sheeler; D Cook; W Malarkey; I Jackson; M L Vance; A Barkan; L Frohman; D L Kleinberg
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.